Concepedia

Emma C. Fink

EC

Statistics

Publications

9

Citations

2.1K

H-Index

9

Active since

2010

Affiliations

Brigham and Women's Hospital(Current)

Broad Institute

Dana-Farber Cancer Institute

Harvard University

University College London

Emma C. Fink is an author at Brigham and Women's Hospital specializing in life sciences, molecular biology, and molecular oncology.

ORCID

Publications per year

2010–2022

9

Publications

9

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Jan Krönke, Emma C. Fink, Paul W. Hollenbach et al. · Nature · 2015 · 836 citations · Full text

, , +8

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

Katherine A. Donovan, An Jian, Radosław P. Nowak et al. · eLife · 2018 · 517 citations · Full text

, , +13

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Mikołaj Słabicki, Zuzanna Kozicka, Georg Petzold et al. · Nature · 2020 · 407 citations · Full text

, , +11

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Emma C. Fink, Marie McConkey, Saurav D. Haldar et al. · Blood · 2018 · 127 citations · Full text

, , +4

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

Marcus Järås, Peter G. Miller, Lisa P. Chu et al. · The Journal of Experimental Medicine · 2014 · 93 citations · Full text

, , +17

1–5 of 9